ABOUT HARPAGO
A SPECIALIST CDMO FOR SOLUBILITY ENHANCEMENT
Over 70% of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders pharmaceutical development and ultimately prevents patients from accessing potentially life-saving treatments.
At Harpago, we tackle this solubility problem through rigorous formulation design and development.
Operating from Ghent, Belgium, one of Europe's most vibrant biotech hubs, we work with emerging biopharma companies across the globe to enhance solubility and bioavailability in discovery, preclinical and early clinical projects.
Over 70% of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders pharmaceutical development and ultimately prevents patients from accessing potentially life-saving treatments.
At Harpago, we tackle this solubility problem through rigorous formulation design and development.
Operating from Ghent, Belgium, one of Europe's most vibrant biotech hubs, we work with emerging biopharma companies across the globe to enhance solubility and bioavailability in discovery, preclinical and early clinical projects.
ABOUT HARPAGO
A SPECIALIST CDMO FOR SOLUBILITY ENHANCEMENT
Over 70% of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders pharmaceutical development and ultimately prevents patients from accessing potentially life-saving treatments.
At Harpago, we tackle this solubility problem through rigorous formulation design and development.
Operating from Ghent, Belgium, one of Europe's most vibrant biotech hubs, we work with emerging biopharma companies across the globe to enhance solubility and bioavailability in discovery, preclinical and early clinical projects.
Over 70% of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders pharmaceutical development and ultimately prevents patients from accessing potentially life-saving treatments.
At Harpago, we tackle this solubility problem through rigorous formulation design and development.
Operating from Ghent, Belgium, one of Europe's most vibrant biotech hubs, we work with emerging biopharma companies across the globe to enhance solubility and bioavailability in discovery, preclinical and early clinical projects.